The OCT-1 activity compared with molecular responses (log reduction in BCR-ABL) at 18 months. Response criteria assessed are suboptimal response (failure to achieve MMR by 18 months) and optimal responses (achievement of 3- to 4-log reduction in BCR-ABL, and more than 4-log reduction by 18 months. Cohorts are divided: (A) All patients irrespective of dose received. (B) Patients receiving less than 600 mg ADD over the first 12 months. (C) Patients who failed to dose escalate to 800 mg ADD after 12 months. (D) Patients who successfully dose escalated to 800 mg ADD after 12 months of therapy.